GE HealthCare to Buy SOFIE Biosciences for $945M, Expanding U.S. PET Radiopharmaceutical Footprint
Event summary
- GE HealthCare to acquire SOFIE Biosciences for $945 million in cash, expected to close in H1 2027.
- SOFIE Biosciences operates 15 CMO sites with 21 cyclotrons in the U.S., enhancing GE HealthCare's 'final mile' PET radiopharmaceutical supply.
- Acquisition aims to strengthen GE HealthCare's theranostics pathway, from cyclotrons to imaging technology and digital workflow tools.
- SOFIE Biosciences' Phase III FAPI-74 asset expands GE HealthCare's pipeline in the fast-growing PET imaging market.
The big picture
The acquisition positions GE HealthCare to capitalize on the expanding PET radiopharmaceutical market, driven by innovative radiotracers and precision care advancements. With approximately 20 PET radiotracers and over 30 radiotherapeutics in development, the deal underscores GE HealthCare's strategy to dominate the theranostics pathway. The $945 million cash transaction highlights the strategic importance of securing reliable supply chains for time-sensitive radiopharmaceuticals.
What we're watching
- Integration Challenges
- How GE HealthCare will integrate SOFIE Biosciences' operations and maintain customer relationships post-acquisition.
- Regulatory Approvals
- The pace at which regulatory approvals will be secured to close the deal by H1 2027.
- Market Expansion
- Whether the acquisition will accelerate GE HealthCare's participation in the growing radiopharmaceutical value stream.
Related topics